Passage Bio (PASG) Receives FDA Clearance of IND Application for PBFT02 Gene Therapy Candidate for Treatment of Patients with Frontotemporal Dementia with Granulin Mutations
Go back to Passage Bio (PASG) Receives FDA Clearance of IND Application for PBFT02 Gene Therapy Candidate for Treatment of Patients with Frontotemporal Dementia with Granulin Mutations| (NASDAQ: PASG) | Delayed: 1.22 -0.02 (1.61%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $1.24 | 52 Week High | $ | |||
| Open | $1.22 | 52 Week Low | $ | |||
| Day High | $1.26 | P/E | N/A | |||
| Day Low | $1.20 | EPS | $ | |||
| Volume | 7,261 | |||||
